Humacyte, Inc. $HUMA Shares Purchased by Woodline Partners LP

Key Points

• Woodline Partners LP increased its stake in Humacyte, Inc. by 38.7% during Q1, owning approximately 2.55% of the company, worth $6.73 million.
• Insider trading was notable, with CEO Laura E. Niklason and Director Brady W. Dougan each selling 591,685 shares at an average price of $1.58.
• Humacyte reported a loss of $0.24 per share in its latest earnings, below the expected loss of $0.15, with revenues of only $0.30 million against estimates of $0.94 million.

Woodline Partners LP boosted its holdings in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 38.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,950,000 shares of the company's stock after purchasing an additional 1,101,198 shares during the quarter. Woodline Partners LP owned approximately 2.55% of Humacyte worth $6,735,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in HUMA. Price T Rowe Associates Inc. MD increased its stake in Humacyte by 20.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 33,870 shares of the company's stock worth $172,000 after acquiring an additional 5,801 shares during the last quarter. MetLife Investment Management LLC increased its stake in Humacyte by 14.4% during the first quarter. MetLife Investment Management LLC now owns 51,442 shares of the company's stock worth $88,000 after acquiring an additional 6,482 shares during the last quarter. ProShare Advisors LLC increased its stake in Humacyte by 30.4% during the fourth quarter. ProShare Advisors LLC now owns 30,852 shares of the company's stock worth $156,000 after acquiring an additional 7,188 shares during the last quarter. Cetera Investment Advisers increased its stake in Humacyte by 48.7% during the fourth quarter. Cetera Investment Advisers now owns 27,880 shares of the company's stock worth $141,000 after acquiring an additional 9,134 shares during the last quarter. Finally, XTX Topco Ltd increased its stake in Humacyte by 22.5% during the first quarter. XTX Topco Ltd now owns 53,797 shares of the company's stock worth $92,000 after acquiring an additional 9,868 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Humacyte news, CEO Laura E. Niklason sold 591,685 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total transaction of $934,862.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brady W. Dougan sold 591,685 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total value of $934,862.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,482,090 shares of company stock valued at $7,466,382. 5.10% of the stock is owned by insiders.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $1.47 on Friday. Humacyte, Inc. has a 1-year low of $1.15 and a 1-year high of $6.77. The business has a 50-day moving average of $2.00 and a 200-day moving average of $2.12. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.45 and a quick ratio of 1.93. The company has a market capitalization of $232.80 million, a price-to-earnings ratio of -3.27 and a beta of 1.87.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The business had revenue of $0.30 million during the quarter, compared to analysts' expectations of $0.94 million. On average, equities analysts anticipate that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on HUMA shares. Barclays started coverage on Humacyte in a research note on Wednesday, August 27th. They set an "overweight" rating and a $3.50 price target for the company. D. Boral Capital restated a "buy" rating and set a $25.00 price target on shares of Humacyte in a research note on Monday, August 11th. Wall Street Zen lowered Humacyte from a "hold" rating to a "sell" rating in a research note on Sunday, August 17th. HC Wainwright dropped their price target on Humacyte from $4.00 to $3.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Finally, TD Cowen decreased their target price on Humacyte from $5.00 to $3.50 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $9.75.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Want to see what other hedge funds are holding HUMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humacyte, Inc. (NASDAQ:HUMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.